Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M mutation hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuhang, Cang, Shundong, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830020/
https://www.ncbi.nlm.nih.gov/pubmed/27071706
http://dx.doi.org/10.1186/s13045-016-0268-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830020/
https://www.ncbi.nlm.nih.gov/pubmed/27071706
http://dx.doi.org/10.1186/s13045-016-0268-z

Ejemplares similares